Just drop those #patents altogether on the basis of them posing a danger to the public and general safely
If the governments funding COVID 19 related R&D are serious about solidarity, they will support the May 29 WHO call for open licensing of inventions, data, know-how, for drugs, vaccines, diagnostics, etc.
#OSI Pres 2016: bad #microsoft keeps blackmailing #linux with software #patents OSI 2017: takes Microsoft bribes OSI+Pres 2018: no comment on Microsoft 2019: Microsoft blackmails Foxconn over Linux, OSI+Pres... no comment!! OSI 2020:
The OSI, which lost its two co-founders in two months (this year), is acting like little but a Microsoft marketing front right now; maybe it's time to just say goodbye and good night to OSI (it's seemingly beyond redemption)
European Patent Office puff pieces come not only in German but also behind paywalls, amplifying patently false claims that are justified because these are mere “interviews” (no fact-checking necessary)
#patents are not rights AT ALL. Neither legally nor technically. Keep on fighting for #ptab and against #swpats
Congratulations to lawyer Paul Clement, who argues his 101st case before the @SCOTUS today. Clement has advocated on several issues, including #patent rights are not natural rights. Read more: https://t.co/Emv55dJiiS
By Bryan Helwig -- About Life Sciences Court Report: We will periodically report on recently filed biotech and pharma litigation. Allergan USA, Inc. v. Prollenium US Inc. 1-20-cv-00104; filed January 23, 2020 in the District Court of Delaware • Plaintiffs: Allergan USA, Inc. and Allergan Industrie SAS • Defendants: Prollenium Medical Technologies Inc. and Prollenium US Inc. Claim: Infringement of U.S. Patent Nos.: • 10,391,202: Hyaluronic acid-based gels including lidocaine • 10,485,896: Hyaluronic acid-based gels including lidocaine Synopsis: Allergan asserts infringement of the '202 and '896 patents. Allergen develops, manufacturers, and distributes dermal filler products including JUVEDÉRM® Ultra XC, JUVEDÉRM®...
By Kevin E. Noonan -- Two papers were filed with the PTAB in Interference No. 106,155 between Senior Party The Broad Institute, Harvard University, and the Massachusetts Institute of Technology, and Junior Party the University of California, Berkeley, the University of Vienna, and Emmanuelle Charpentier (collectively, "CVC"). On February 13, 2020, the parties filed a Joint Stipulation to Extend Time for time periods 4-6; the deadlines for the responses due during those time periods now are as follows: TIME PERIOD 1 -- October 4, 2019 File motions -- October 14, 2019 File priority statements (but serve one business day later)...
As consumers place greater value on quality goods available through a transparent supply chain, Stony Brook, N.Y., Applied DNA Sciences, Inc., announced its receipt of a Chinese patent and notice of allowability for its Canadian patent application for its Encrypted Optical Markers for Security Applications.